Back to top
more

Labcorp (LH)

(Delayed Data from NYSE)

$229.69 USD

229.69
406,015

-1.01 (-0.44%)

Updated Aug 29, 2024 04:00 PM ET

After-Market: $229.74 +0.05 (0.02%) 7:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 30% (175 out of 251)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Align Technology (ALGN) Q4 Earnings Top Estimates, Margins Down

by Zacks Equity Research

Robust segmental growth and iTero sales are driving Align Technology's (ALGN) Q4 top line.

Align Technology (ALGN) Surpasses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Align Technology (ALGN) delivered earnings and revenue surprises of 6.39% and 1.41%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

LabCorp (LH) Gains But Lags Market: What You Should Know

by Zacks Equity Research

LabCorp (LH) closed at $273.18 in the latest trading session, marking a +0.08% move from the prior day.

Thermo Fisher (TMO) Q4 Earnings Beat Estimates, Margins Down

by Zacks Equity Research

Thermo Fisher's (TMO) Q4 earnings surpassed the Zacks Consensus Estimate with strength across the Analytical Instruments segment driving the top line.

IDEXX (IDXX) Q4 Earnings Beat Estimates, Gross Margin Up

by Zacks Equity Research

Growth in CAG Diagnostics revenues and CAG Diagnostics capital instrument revenues drove IDEXX (IDXX) Q4 revenues.

Here's Why You Should Retain Edwards Lifesciences (EW) Stock

by Zacks Equity Research

Investors are optimistic about Edwards Lifesciences (EW) on continued strong adoption of the SAPIEN 3 Ultra platform and the PASCAL system.

Here's Why You Should Retain West Pharmaceutical (WST) Now

by Zacks Equity Research

West Pharmaceutical (WST) continues to gain momentum on the back of strength in the Proprietary Products business. However, forex woes persist.

Diagnostics Sales to Drive Hologic's (HOLX) Q1 Earnings

by Zacks Equity Research

Strength in the Diagnostics division is likely to have contributed to Hologic's (HOLX) fiscal first-quarter revenues.

Zacks.com featured highlights include: Crocs, Laboratory Corp. of America, CBRE Group, Tesla and AGCO

by Zacks Equity Research

Crocs, Laboratory Corp. of America, CBRE Group, Tesla and AGCO are included in this blog.

BD (BDX) Gears Up for Q1 Earnings: What's in the Offing?

by Zacks Equity Research

Continued strength in BD's (BDX) Life Sciences and Interventional segments is expected to have driven up Q1 sales.

Stryker (SYK) Q4 Earnings Miss Estimates, Revenues Beat

by Zacks Equity Research

Despite pandemic-led disruptions, Stryker's (SYK) fourth-quarter earnings reflect strong performance across its segments.

Hologic (HOLX) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Strength in Diagnostics and Breast Health businesses is likely to have contributed to Hologic's (HOLX) fiscal first-quarter revenues.

Abiomed (ABMD) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Continued strength in Abiomed's (ABMD) Impella product line is expected to have driven up Q3 sales.

LabCorp (LH) Stock Moves -0.4%: What You Should Know

by Zacks Equity Research

LabCorp (LH) closed the most recent trading day at $265.73, moving -0.4% from the previous trading session.

Sanghamitra Saha headshot

5 Top-Ranked Stocks Likely to Beat Earnings Estimates

by Sanghamitra Saha

These top-ranked stocks are likely to beat on the bottom line in their next releases.

This 1 Medical Stock Could Beat Earnings: Why It Should Be on Your Radar

by Zacks Equity Research

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Rise in COVID Tests to Boost Thermo Fisher (TMO) Q4 Earnings

by Zacks Equity Research

With the emergence of the Omicron variant through the Q4 months globally, Thermo Fisher's (TMO) Life-Science Solutions segment is likely to have registered strong top-line contributions.

Boston Scientific (BSX) Hit by Procedure Deferrals Amid COVID

by Zacks Equity Research

Although Boston Scientific (BSX) reports margin expansion on a year-over-year basis, the decline in R&D expenses is concerning.

Here's Why You Should Add LabCorp (LH) to Your Portfolio Now

by Zacks Equity Research

Investors are optimistic about LabCorp (LH) backed by increased COVID-19 testing demand and development in high-growth areas.

LabCorp (LH) Gains As Market Dips: What You Should Know

by Zacks Equity Research

LabCorp (LH) closed at $271.57 in the latest trading session, marking a +0.26% move from the prior day.

Rise in COVID-19 Test Demand to Boost Abbott (ABT) Q4 Earnings

by Zacks Equity Research

With the latest surge in COVID infections due to the more contagious Omicron variant, Abbott (ABT) is expected to report sequentially stronger diagnostics results for the fourth quarter.

Walgreens (WBA), Village MD Plan to Expand Into Arizona

by Zacks Equity Research

Walgreens (WBA) and VillageMD to improve access to overall care for patients with chronic conditions by opening eight new Village Medical at Walgreens primary care practices in the Tucson area.

LabCorp (LH) Stock Moves -0.42%: What You Should Know

by Zacks Equity Research

LabCorp (LH) closed the most recent trading day at $270.87, moving -0.42% from the previous trading session.

Zimmer Biomet's (ZBH) Pandemic Recovery Slow, Margin Woes Stay

by Zacks Equity Research

The third quarter brings greater COVID-related pressure than expected for Zimmer Biomet (ZBH).

Here's Why You Should Retain STERIS (STE) Stock for Now

by Zacks Equity Research

Investors are optimistic about STERIS' (STE) strong segmental performance and bullish 2022 outlook.